Tvardi Therapeutics (TVRD) Cash & Equivalents: 2013-2017
Historic Cash & Equivalents for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to $11.8 million.
- Tvardi Therapeutics' Cash & Equivalents rose 117.32% to $11.8 million in Q3 2017 from the same period last year, while for Sep 2017 it was $11.8 million, marking a year-over-year increase of 117.32%. This contributed to the annual value of $12.1 million for FY2016, which is 19.93% down from last year.
- Tvardi Therapeutics' Cash & Equivalents amounted to $11.8 million in Q3 2017, which was up 25.23% from $9.4 million recorded in Q2 2017.
- Over the past 5 years, Tvardi Therapeutics' Cash & Equivalents peaked at $111.1 million during Q3 2015, and registered a low of $690,000 during Q1 2013.
- Moreover, its 3-year median value for Cash & Equivalents was $11.8 million (2017), whereas its average is $24.8 million.
- As far as peak fluctuations go, Tvardi Therapeutics' Cash & Equivalents surged by 9,615.65% in 2014, and later plummeted by 95.12% in 2016.
- Tvardi Therapeutics' Cash & Equivalents (Quarterly) stood at $12.4 million in 2013, then surged by 326.18% to $52.7 million in 2014, then tumbled by 71.33% to $15.1 million in 2015, then declined by 19.93% to $12.1 million in 2016, then skyrocketed by 117.32% to $11.8 million in 2017.
- Its Cash & Equivalents stands at $11.8 million for Q3 2017, versus $9.4 million for Q2 2017 and $5.3 million for Q1 2017.